From “Botox in a bottle” to castor oil and face taping, Dermatology Times reviews the evidence behind 3 viral dermatology trends from October.
|Articles|March 24, 2020
The Mainstream Patient: March 24
Author(s)Morgan Petronelli
Introducing The Mainstream Patient, a weekly glimpse into what your patients may be reading in the media about skin health.
Advertisement
Introducing The Mainstream Patient, a weekly glimpse into what your patients may be reading in the media about skin health.
This week’s edition is jam-packed with content from Allure and Real Simple, who tackle a variety of topics including treatments for melasma, pityrosporum folliculitis and keratosis pilaris. Real Simple also dives into the realm of anti-aging with stories tackling collagen and other anti-aging techniques.
Advertisement
Related to this article
Dermatology PAs unpack 4 frightening skin care myths and trends, from sunscreen misinformation and citrus DIYs to overusing actives and beef tallow.
The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.
Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting CSU evidence.
Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
The Scariest Skin Care Trends Haunting Patients This Halloween
3
October Social Media Mythbusters: 3 Viral Beauty Claims, Debunked
4
Improving Early Identification and Escalation of HS
5